Progressive Supranuclear Palsy and Statin Use.
case-control
progressive supranuclear palsy
statins
tauopathy
Journal
Movement disorders : official journal of the Movement Disorder Society
ISSN: 1531-8257
Titre abrégé: Mov Disord
Pays: United States
ID NLM: 8610688
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
26
11
2019
revised:
03
03
2020
accepted:
05
03
2020
pubmed:
29
3
2020
medline:
28
4
2021
entrez:
29
3
2020
Statut:
ppublish
Résumé
Statins were proposed to be neuroprotective; however, the effects are unknown in progressive supranuclear palsy (PSP), a pure tauopathy. Data of 284 PSP cases and 284 age-matched, sex-matched, and race-matched controls were obtained from the environmental and genetic PSP (ENGENE-PSP) study. Cases were evaluated with the PSP Rating Scale, Unified Parkinson's Disease Rating Scale, Mattis Dementia Rating Scale, and Neuropsychiatric Inventory. Statin associations with PSP risk, onset age, and disease features were analyzed. Univariate models showed lower PSP risk for type 1 statin users (simvastatin, lovastatin, pravastatin). After adjusting for confounding variables, statin use and lower PSP risk association remained only at a trend level. For PSP cases, type 1 statins were associated with 1-year older onset age; type 2 statins (atorvastatin, rosuvastatin) were associated with the lower PSP Rating Scale and Unified Parkinson's Disease Rating Scale. Statins may have inverse associations with PSP risk and motor impairment. Randomized prospective studies are required to confirm this effect. © 2020 International Parkinson and Movement Disorder Society.
Identifiants
pubmed: 32220093
doi: 10.1002/mds.28038
pmc: PMC7375943
mid: NIHMS1584066
doi:
Substances chimiques
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1253-1257Subventions
Organisme : NIA NIH HHS
ID : R01 AG024040
Pays : United States
Informations de copyright
© 2020 International Parkinson and Movement Disorder Society.
Références
Mov Disord. 2017 Jun;32(6):853-864
pubmed: 28467028
Neurology. 1996 Jul;47(1):1-9
pubmed: 8710059
Exp Neurol. 2011 Jul;230(1):27-34
pubmed: 20406638
Mov Disord. 2016 May;31(5):644-52
pubmed: 26854325
Parkinsonism Relat Disord. 2019 Sep;66:166-170
pubmed: 31420308
Parkinsonism Relat Disord. 2011 Nov;17(9):683-8
pubmed: 21741294
Parkinsonism Relat Disord. 2016 Jan;22 Suppl 1:S29-33
pubmed: 26382841
Lancet Neurol. 2017 Jul;16(7):552-563
pubmed: 28653647
J Clin Cell Immunol. 2014;5:
pubmed: 25525560
J Neuropathol Exp Neurol. 2009 Mar;68(3):314-25
pubmed: 19225406
Alzheimers Res Ther. 2017 Feb 17;9(1):10
pubmed: 28212683
Parkinsonism Relat Disord. 2016 Jan;22 Suppl 1:S34-6
pubmed: 26421392
J Alzheimers Dis. 2011;23(2):307-18
pubmed: 21098985
Cochrane Database Syst Rev. 2016 Jan 04;(1):CD003160
pubmed: 26727124
Antimicrob Agents Chemother. 2016 Aug 22;60(9):5111-21
pubmed: 27324773